PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27207449-5 2017 RESULTS: For patients continuing DMF BID (BID/BID), annualized relapse rates were 0.202, 0.163, 0.139, 0.143, and 0.138 (years 1-5, respectively) and 63%, 73%, and 88% were free of new or enlarging T2 hyperintense lesions, new T1 hypointense lesions, and gadolinium-enhanced lesions, respectively, at year 5. Dimethyl Fumarate 33-36 BH3 interacting domain death agonist Homo sapiens 37-40 27207449-5 2017 RESULTS: For patients continuing DMF BID (BID/BID), annualized relapse rates were 0.202, 0.163, 0.139, 0.143, and 0.138 (years 1-5, respectively) and 63%, 73%, and 88% were free of new or enlarging T2 hyperintense lesions, new T1 hypointense lesions, and gadolinium-enhanced lesions, respectively, at year 5. Dimethyl Fumarate 33-36 BH3 interacting domain death agonist Homo sapiens 42-45 27207449-5 2017 RESULTS: For patients continuing DMF BID (BID/BID), annualized relapse rates were 0.202, 0.163, 0.139, 0.143, and 0.138 (years 1-5, respectively) and 63%, 73%, and 88% were free of new or enlarging T2 hyperintense lesions, new T1 hypointense lesions, and gadolinium-enhanced lesions, respectively, at year 5. Dimethyl Fumarate 33-36 BH3 interacting domain death agonist Homo sapiens 42-45 25270680-6 2014 Similarly, mean percentage reduction from baseline in median NABT MTR was -0.392% with placebo vs increases of 0.190% (p = 0.0006) and 0.115% (p = 0.0029) with delayed-release DMF BID and TID, respectively. Dimethyl Fumarate 176-179 BH3 interacting domain death agonist Homo sapiens 180-183 27683214-2 2016 FTY and TFN are recommended with once-daily doses with no up-titration, whereas DMF treatment is recommended twice-daily (BID) and is initiated with a 7-day starter dose of 120 mg BID before up-titration to the maintenance dose of 240 mg BID. Dimethyl Fumarate 80-83 BH3 interacting domain death agonist Homo sapiens 122-125 27683214-10 2016 Of DMF patients with a confirmed starting dose of 120 mg BID with >=12 months follow-up (n = 26), the percentage who were prescribed dose up-titrations to the recommended maintenance DMF dose was 23.1 % at 1-3 months, 26.9 % at 4-6 months, 42.3 % at 7-9 months, and 0 % at 10-12 months. Dimethyl Fumarate 3-6 BH3 interacting domain death agonist Homo sapiens 57-60 25557371-5 2015 RESULTS: A total of 2301 patients were randomized and received treatment with placebo (n = 771) or DMF BID (n = 769) or TID (n = 761). Dimethyl Fumarate 99-102 BH3 interacting domain death agonist Homo sapiens 103-106 25557371-6 2015 DMF significantly reduced the annualized relapse rate beginning in weeks 0-12 (BID, P = 0.0159; TID, P = 0.0314); the proportion of patients relapsed beginning at week 10 (BID, P = 0.0427) and week 12 (TID, P = 0.0451); and the proportion of patients with 12-week confirmed disability progression beginning at week 62 (BID, P = 0.0454) and week 72 (TID, P = 0.0399), compared with placebo. Dimethyl Fumarate 0-3 BH3 interacting domain death agonist Homo sapiens 79-82 25557371-6 2015 DMF significantly reduced the annualized relapse rate beginning in weeks 0-12 (BID, P = 0.0159; TID, P = 0.0314); the proportion of patients relapsed beginning at week 10 (BID, P = 0.0427) and week 12 (TID, P = 0.0451); and the proportion of patients with 12-week confirmed disability progression beginning at week 62 (BID, P = 0.0454) and week 72 (TID, P = 0.0399), compared with placebo. Dimethyl Fumarate 0-3 BH3 interacting domain death agonist Homo sapiens 172-175 25557371-6 2015 DMF significantly reduced the annualized relapse rate beginning in weeks 0-12 (BID, P = 0.0159; TID, P = 0.0314); the proportion of patients relapsed beginning at week 10 (BID, P = 0.0427) and week 12 (TID, P = 0.0451); and the proportion of patients with 12-week confirmed disability progression beginning at week 62 (BID, P = 0.0454) and week 72 (TID, P = 0.0399), compared with placebo. Dimethyl Fumarate 0-3 BH3 interacting domain death agonist Homo sapiens 172-175 25557371-8 2015 DMF significantly reduced the odds of having a higher number of gadolinium-enhancing lesions by 88% (BID) and 75% (TID) and the mean number of new or enlarging T2 lesions by 72% (BID) and 67% (TID), from the first post-baseline magnetic resonance imaging assessment at 24 weeks (all P < 0.0001 versus placebo). Dimethyl Fumarate 0-3 BH3 interacting domain death agonist Homo sapiens 101-104 25557371-8 2015 DMF significantly reduced the odds of having a higher number of gadolinium-enhancing lesions by 88% (BID) and 75% (TID) and the mean number of new or enlarging T2 lesions by 72% (BID) and 67% (TID), from the first post-baseline magnetic resonance imaging assessment at 24 weeks (all P < 0.0001 versus placebo). Dimethyl Fumarate 0-3 BH3 interacting domain death agonist Homo sapiens 179-182 25750916-5 2015 In a subset of patients (MRI cohort), DMF BID and TID reduced the mean number of new/enlarging T2-hyperintense lesions by 78% and 73%, gadolinium-enhancing lesion activity by 83% and 70%, and mean number of new nonenhancing T1-hypointense lesions by 65% and 64% (all P < 0.0001 vs. placebo). Dimethyl Fumarate 38-41 BH3 interacting domain death agonist Homo sapiens 42-45 24990854-5 2015 At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001), risk of relapse by 54% and 57% (both p < 0.0001), and risk of 12-week confirmed disability progression by 71% (p < 0.0001) and 47% (p = 0.0085) versus placebo. Dimethyl Fumarate 28-31 BH3 interacting domain death agonist Homo sapiens 32-35 24990854-6 2015 In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo). Dimethyl Fumarate 54-57 BH3 interacting domain death agonist Homo sapiens 58-61 25315404-7 2014 FINDINGS: The integrated analysis included 2301 patients treated with delayed-release DMF BID (n = 769) or TID (n = 761) or placebo (n = 771). Dimethyl Fumarate 86-89 BH3 interacting domain death agonist Homo sapiens 90-93 24989666-1 2014 In the Phase 3 DEFINE study, delayed-release dimethyl fumarate (DMF) 240 mg twice (BID) and three times daily (TID) significantly reduced the mean number of new or enlarging T2-hyperintense lesions and gadolinium-enhancing (Gd+) lesion activity at 2 years in patients (MRI cohort; n = 540) with relapsing-remitting MS. Dimethyl Fumarate 45-62 BH3 interacting domain death agonist Homo sapiens 83-86 24989666-1 2014 In the Phase 3 DEFINE study, delayed-release dimethyl fumarate (DMF) 240 mg twice (BID) and three times daily (TID) significantly reduced the mean number of new or enlarging T2-hyperintense lesions and gadolinium-enhancing (Gd+) lesion activity at 2 years in patients (MRI cohort; n = 540) with relapsing-remitting MS. Dimethyl Fumarate 64-67 BH3 interacting domain death agonist Homo sapiens 83-86 24989666-3 2014 Reductions in lesion counts with delayed-release DMF BID and TID, respectively, vs. placebo were apparent by the first MRI assessment at 6 months [T2-hyperintense: 80 and 69 % reduction (both P < 0.0001); Gd+, 94 and 81 % reduction (both P < 0.0001); T1-hypointense: 58 % (P < 0.0001) and 48 % (P = 0.0005) reduction] and maintained at 1 and 2 years. Dimethyl Fumarate 49-52 BH3 interacting domain death agonist Homo sapiens 53-56 24989666-5 2014 Relative reductions in brain atrophy from baseline to 2 years (21 % reduction; P = 0.0449) and 6 months to 2 years (30 % reduction; P = 0.0214) were statistically significant for delayed-release DMF BID. Dimethyl Fumarate 195-198 BH3 interacting domain death agonist Homo sapiens 199-202